Terms: = Breast cancer AND MAF, MGC71685, 4094, ENSG00000178573
127 results:
1. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Goetz MP; Bagegni NA; Batist G; Brufsky A; Cristofanilli MA; Damodaran S; Daniel BR; Fleming GF; Gradishar WJ; Graff SL; Grosse Perdekamp MT; Hamilton E; Lavasani S; Moreno-Aspitia A; O'Connor T; Pluard TJ; Rugo HS; Sammons SL; Schwartzberg LS; Stover DG; Vidal GA; Wang G; Warner E; Yerushalmi R; Plourde PV; Portman DJ; Gal-Yam EN
Ann Oncol; 2023 Dec; 34(12):1141-1151. PubMed ID: 38072514
[TBL] [Abstract] [Full Text] [Related]
2. maf and ERα Coordinately Drive Metastatic Programs in breast cancer.
Cancer Discov; 2024 Jan; 14(1):15. PubMed ID: 37975647
[TBL] [Abstract] [Full Text] [Related]
3. maf amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis.
Llorente A; Blasco MT; Espuny I; Guiu M; Ballaré C; Blanco E; Caballé A; Bellmunt A; Salvador F; Morales A; Nuñez M; Loren G; Imbastari F; Fidalgo M; Figueras-Puig C; Gibler P; Graupera M; Monteiro F; Riera A; Holen I; Avgustinova A; Di Croce L; Gomis RR
Nat Cell Biol; 2023 Dec; 25(12):1833-1847. PubMed ID: 37945904
[TBL] [Abstract] [Full Text] [Related]
4. LncRNA mafG-AS1 is involved in human cancer progression.
Li P; Ma X; Gu X
Eur J Med Res; 2023 Nov; 28(1):497. PubMed ID: 37941063
[TBL] [Abstract] [Full Text] [Related]
5. cancer stem cell-derived CHI3L1 activates the maf/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer.
Ji S; Yu H; Zhou D; Fan X; Duan Y; Tan Y; Lang M; Shao G
J Transl Med; 2023 Oct; 21(1):721. PubMed ID: 37838657
[TBL] [Abstract] [Full Text] [Related]
6. Carcinogenic roles of mafG-AS1 in human cancers.
Ahmadi M; Morshedzadeh F; Ghaderian SMH; Mousavi P; Habibipour L; Peymani M; Abbaszadegan MR; Ghafouri-Fard S
Clin Transl Oncol; 2024 Jan; 26(1):52-68. PubMed ID: 37351806
[TBL] [Abstract] [Full Text] [Related]
7. The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative breast cancer: A Systemic Review and Meta-Analysis.
Ergun Y; Akagunduz B; Karacin C; Turker S; Ucar G
Clin Breast Cancer; 2023 Aug; 23(6):567-575. PubMed ID: 37336652
[TBL] [Abstract] [Full Text] [Related]
8. Valuing vicinity: Memory attention framework for context-based semantic segmentation in histopathology.
Ester O; Hörst F; Seibold C; Keyl J; Ting S; Vasileiadis N; Schmitz J; Ivanyi P; Grünwald V; Bräsen JH; Egger J; Kleesiek J
Comput Med Imaging Graph; 2023 Jul; 107():102238. PubMed ID: 37207396
[TBL] [Abstract] [Full Text] [Related]
9. Metastasis prevention with bone-targeted agents: a complex interaction between the microenvironment and tumour biology.
Coleman R
J Bone Miner Metab; 2023 May; 41(3):290-300. PubMed ID: 37162605
[TBL] [Abstract] [Full Text] [Related]
10. Risky alcohol consumption among women in Australia attending breast screening services: an exploratory cross-sectional study.
Grigg J; Manning V; Cheetham A; Greenwood CJ; Youssef G; Lockie D; Bell R; Stragalinos P; Bernard C; Lubman DI
Addiction; 2023 Aug; 118(8):1493-1506. PubMed ID: 37057463
[TBL] [Abstract] [Full Text] [Related]
11. Selenadiazole derivative-loaded metal azolate frameworks facilitate NK cell immunotherapy by sensitizing tumor cells and shaping immuno-suppressive microenvironments.
Yang Y; Jiang Y; Xie B; Shi S; Pi F; Chen M; Sang C; Xu L; Chen T
Biomater Sci; 2023 Feb; 11(4):1517-1529. PubMed ID: 36606484
[TBL] [Abstract] [Full Text] [Related]
12. Expression of Treg-associated lncRNAs in breast cancer.
Moallemi-Rad L; Ghorbani A; Dadyar M; Hussen BM; Rasul MF; Eslami S; Taheri M; Jamali E; Ghafouri-Fard S
Pathol Res Pract; 2023 Jan; 241():154270. PubMed ID: 36535227
[TBL] [Abstract] [Full Text] [Related]
13. Unique ESR1 and ESR2 estrogen receptor gene variants associated with altered risk of triple-negative breast cancer: A case-control study.
Sghaier I; Zidi S; El-Ghali RM; Daldoul A; Aimagambetova G; Almawi WY
Gene; 2023 Jan; 851():146969. PubMed ID: 36261089
[TBL] [Abstract] [Full Text] [Related]
14. ATM c.7570G>C is a high-risk allele for breast cancer.
Kankuri-Tammilehto M; Tervasmäki A; Kraatari-Tiri M; Rahikkala E; Pylkäs K; Kuismin O
Int J Cancer; 2023 Feb; 152(3):429-435. PubMed ID: 36161273
[TBL] [Abstract] [Full Text] [Related]
15. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
Fernandez-Garcia D; Nteliopoulos G; Hastings RK; Rushton A; Page K; Allsopp RC; Ambasager B; Gleason K; Guttery DS; Ali S; Charles Coombes R; Shaw JA
Br J Cancer; 2022 Nov; 127(10):1858-1864. PubMed ID: 36088510
[TBL] [Abstract] [Full Text] [Related]
16. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
Gerratana L; Movarek M; Wehbe F; Katam N; Mahalingam D; Donahue J; Shah A; Chae YK; Mulcahy M; Tsarwhas D; Villaflor V; Kalyan A; Hussein M; Patel J; Chandra S; Platanias LC; Gradishar W; Cristofanilli M; Behdad A
JCO Precis Oncol; 2022 Jun; 6():e2100289. PubMed ID: 35772051
[TBL] [Abstract] [Full Text] [Related]
17. Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS.
Callens C; Bidard FC; Curto-Taribo A; Trabelsi-Grati O; Melaabi S; Delaloge S; Hardy-Bessard AC; Bachelot T; Clatot F; De La Motte Rouge T; Canon JL; Arnould L; Andre F; Marques S; Stern MH; Pierga JY; Vincent-Salomon A; Benoist C; Jeannot E; Berger F; Bieche I; Pradines A
Anal Chem; 2022 Apr; 94(16):6297-6303. PubMed ID: 35416669
[TBL] [Abstract] [Full Text] [Related]
18. Machine Learning Identifies Pan-cancer Landscape of Nrf2 Oxidative Stress Response Pathway-Related Genes.
Li N; Zhan X
Oxid Med Cell Longev; 2022; 2022():8450087. PubMed ID: 35242279
[TBL] [Abstract] [Full Text] [Related]
19. Oestradiol Contributes to Differential Antitumour Effects of Adjuvant Zoledronic Acid Observed Between Pre- and Post-Menopausal Women.
Canuas-Landero VG; George CN; Lefley DV; Corness H; Muthana M; Wilson C; Ottewell PD
Front Endocrinol (Lausanne); 2021; 12():749428. PubMed ID: 34733240
[TBL] [Abstract] [Full Text] [Related]
20.
Paterson AHG; Lucas PC; Anderson SJ; Mamounas EP; Brufsky A; Baez-Diaz L; King KM; Lad T; Robidoux A; Finnigan M; Sampayo M; Tercero JC; Mairet JJ; Wolff AC; Fehrenbacher L; Wolmark N; Gomis RR
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34377934
[TBL] [Abstract] [Full Text] [Related]
[Next]
